ACADIA Pharmaceuticals Inc logo

ACAD - ACADIA Pharmaceuticals Inc Share Price

$52.83 0.8  1.6%

Last Trade - 22/01/21

Sector
Healthcare
Size
Large Cap
Market Cap £6.02bn
Enterprise Value £5.55bn
Revenue £305.2m
Position in Universe 1003rd / 6626
Bullish
Bearish
Unlock ACAD Revenue
Momentum
Relative Strength (%)
1m -10.4%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -11.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.12 0.061 17.3 124.9 223.8 339.1 444.1 682.7 +390%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, ACADIAPharmaceuticals Inc. revenues increased 33% to $320.7M. Netloss increased 18% to $214.8M. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Higher net loss reflects OtherResearch and development increase of 47% to $233.4M(expense), General And Administrative Expencess increase of16% to $230.4M (expense), Interest income.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ACAD Revenue Unlock ACAD Revenue

Net Income

ACAD Net Income Unlock ACAD Revenue

Normalised EPS

ACAD Normalised EPS Unlock ACAD Revenue

PE Ratio Range

ACAD PE Ratio Range Unlock ACAD Revenue

Dividend Yield Range

ACAD Dividend Yield Range Unlock ACAD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ACAD EPS Forecasts Unlock ACAD Revenue
Profile Summary

ACADIA Pharmaceuticals Inc. (ACADIA) is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines to address the medical needs in central nervous system disorders. The Company's lead product, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA’s developments are focused on pimavanserin for additional neuropsychiatric conditions, trofinetide for Rett syndrome, ACP-044 for pain management and an early-stage muscarinic receptor program.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated January 16, 1997
Public Since May 27, 2004
No. of Shareholders: 35,000
No. of Employees: 580
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 158,978,087
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ACAD Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ACAD
Upcoming Events for ACAD
Wednesday 24th February, 2021 Estimate
Q4 2020 ACADIA Pharmaceuticals Inc Earnings Release
Wednesday 5th May, 2021 Estimate
Q1 2021 ACADIA Pharmaceuticals Inc Earnings Release
Frequently Asked Questions for ACADIA Pharmaceuticals Inc
What is the ACADIA Pharmaceuticals Inc share price?

As of 22/01/21, shares in ACADIA Pharmaceuticals Inc are trading at $52.83, giving the company a market capitalisation of £6.02bn. This share price information is delayed by 15 minutes.

How has the ACADIA Pharmaceuticals Inc share price performed this year?

Shares in ACADIA Pharmaceuticals Inc are currently trading at $52.83 and the price has moved by 23.36% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the ACADIA Pharmaceuticals Inc price has moved by 6.51% over the past year.

What are the analyst and broker recommendations for ACADIA Pharmaceuticals Inc?

Of the analysts with advisory recommendations for ACADIA Pharmaceuticals Inc, there are there are currently 8 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for ACADIA Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will ACADIA Pharmaceuticals Inc next release its financial results?

ACADIA Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the ACADIA Pharmaceuticals Inc dividend yield?

ACADIA Pharmaceuticals Inc does not currently pay a dividend.

Does ACADIA Pharmaceuticals Inc pay a dividend?

ACADIA Pharmaceuticals Inc does not currently pay a dividend.

When does ACADIA Pharmaceuticals Inc next pay dividends?

ACADIA Pharmaceuticals Inc does not currently pay a dividend.

How do I buy ACADIA Pharmaceuticals Inc shares?

To buy shares in ACADIA Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of ACADIA Pharmaceuticals Inc?

Shares in ACADIA Pharmaceuticals Inc are currently trading at $52.83, giving the company a market capitalisation of £6.02bn.

Where are ACADIA Pharmaceuticals Inc shares listed? Where are ACADIA Pharmaceuticals Inc shares listed?

Here are the trading details for ACADIA Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ACAD
What kind of share is ACADIA Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, ACADIA Pharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a ACADIA Pharmaceuticals Inc share price forecast 2021?

Shares in ACADIA Pharmaceuticals Inc are currently priced at $52.83. At that level they are trading at 18.63% discount to the analyst consensus target price of 0.00.

Analysts covering ACADIA Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.837 for the next financial year.

How can I tell whether the ACADIA Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ACADIA Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 0.65%. At the current price of $52.83, shares in ACADIA Pharmaceuticals Inc are trading at 9.55% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the ACADIA Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for ACADIA Pharmaceuticals Inc.

Who are the key directors of ACADIA Pharmaceuticals Inc?

ACADIA Pharmaceuticals Inc's management team is headed by:

Laura Brege - IND
Stephen Biggar - CHM
Stephen Davis - CEO
Srdjan Stankovic - PRE
Edmund Harrigan - IND
Julian Baker - IND
James Daly - IND
Michael Yang - EVP
Austin Kim - EVP
Elena Ridloff - CFO
Ponni Subbiah - SVP
Stephanie Fagan - SVP
Mark Schneyer - SVP
Gudarz Davar - EVP
Elizabeth Garofalo - DRC
Who are the major shareholders of ACADIA Pharmaceuticals Inc?

Here are the top five shareholders of ACADIA Pharmaceuticals Inc based on the size of their shareholding:

Baker Bros. Advisors LP Hedge Fund
Percentage owned: 26.36% (41.9m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 12.4% (19.7m shares)
T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 6.63% (10.5m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 6.52% (10.4m shares)
Fidelity Growth Company Fund Mutual Fund
Percentage owned: 4.58% (7.28m shares)
Similar to ACAD
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.